Date: 2017-04-17
Type of
information: Presentation of results at a congress
phase: 2
Announcement: presentation of results at the Digestive Disease Week (DDW) 2017
Company: Albireo Pharma (USA - MA) Albireo (Sweden) EA Pharma (Japan)
Product: elobixibat
Action
mechanism:
- ileal bile acid transporter (IBAT) inhibitor. Elobixibat is a first-in-class compound with a novel physiological mechanism of action. It acts locally in the gut with minimal systemic exposure and modulates the enterohepatic circulation of bile acids by a partial inhibition of the Ileal Bile Acid Transporter (IBAT). This increases colonic fluid secretion and motility.
- EA Pharma, a subsidiary of Eisai Co., Ltd. focused in the gastrointestinal disease space, is the exclusive licensee of elobixibat for the treatment of gastrointestinal disorders in Japan and other select countries in Asia .
Disease: chronic constipation
Therapeutic
area: Gastrointestinal diseases - Digestive diseases
Country: Japan
Trial
details:
Latest
news:
- • On April 27, 2017, Albireo Pharma, a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that clinical data from a Phase 2 study of elobixibat in chronic constipation conducted by EA Pharma Co., Ltd. in Japan is scheduled to be presented at Digestive Disease Week (DDW) 2017. Subsequent to completion of the Phase 2 clinical trial being presented at DDW, EA Pharma conducted a Phase 3 trial of elobixibat in chronic constipation with positive results and submitted an application for regulatory approval in Japan . Subject to receipt of regulatory approval, EA Pharma plans to co-market elobixibat in Japan with Mochida Pharmaceutical.
Details of the DDW presentation are as follows:
Title: Determining a clinical optimal dose of elobixibat, a novel IBAT inhibitor, in Japanese patients with chronic
constipation: a multicenter, randomized, double-blind,
placebo-controlled study. Atsushi Nakajima , MD, PhD; Division of Hepatogastroenterology, Yokohama City University Graduate School of Medicine, Japan
Is
general: Yes
